The BAIAP2L1 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-HEP-1 human hepatocellular carcinoma cell line. This product provides a mixed population of edited cells with disruption of the BAIAP2L1 gene, enabling loss-of-function studies without clonal selection. The polyclonal format reduces the risk of clonal artifacts and better represents the average response of the edited cell pool, making it suitable for functional genomics and drug target validation.
The SK-HEP-1 cell line was originally established from the ascites of a patient with liver adenocarcinoma and exhibits a mesenchymal, invasive phenotype characteristic of metastatic hepatocellular carcinoma. This cell line is widely employed in cancer biology research to model tumor cell migration, invasion, and the molecular mechanisms driving hepatocellular carcinoma progression. Its aggressive behavior makes it especially valuable for evaluating genes involved in cancer metastasis.
BAIAP2L1 functions as a critical effector for the small GTPases Rac1 and Cdc42, linking their activation to actin cytoskeleton reorganization. Upon activation by upstream signals such as the insulin receptor and integrin-mediated adhesion, BAIAP2L1 interacts with the WAVE complex and the Arp2/3 complex to promote actin polymerization, driving the formation of filopodia and membrane protrusions. Additionally, BAIAP2L1 associates with IRS4 to modulate insulin-stimulated PI3K/Akt signaling, thereby influencing cell proliferation and survival. Key downstream effectors include Ena/VASP proteins, which further regulate actin filament elongation. This dual role positions BAIAP2L1 at the intersection of cytoskeletal dynamics and growth factor signaling.
In the context of the SK-HEP-1 hepatocellular carcinoma model, BAIAP2L1 is predicted to play a major role in sustaining the invasive and mesenchymal phenotype. By disrupting BAIAP2L1 expression, these polyclonal knockout cells enable researchers to dissect the contribution of BAIAP2L1-mediated actin dynamics to tumor cell motility, invasion, and metastatic potential. The model also facilitates examination of how BAIAP2L1 loss impacts insulin-stimulated PI3K/Akt signaling, which is often deregulated in liver cancer. These polyclonal cells provide a physiologically relevant system for interrogating BAIAP2L1-dependent pathways in a cell line that already harbors aggressive cancer characteristics.
This BAIAP2L1 knockout polyclonal cell population is ideally suited for hepatocellular carcinoma metastasis research, insulin signaling pathway analysis, and cancer cell invasion assays. Representative techniques include Western blotting, Transwell migration and invasion assays, and immunofluorescence staining of F-actin. Additionally, phospho-Akt ELISA and cell proliferation assays can be used to evaluate alterations in PI3K/Akt signaling and growth rates. These cells support phenotypic screening and drug target validation studies. For further information, please contact Ascent Research.
